ReVAMPP Network—NIAID Plans $100 Million for Pandemic Preparedness

Funding News Edition:
See more articles in this edition

NIAID published three notices of funding opportunities (NOFOs) to launch a new Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network.

Two of the NOFOs seek applications for research centers focused on specific virus families, and the third NOFO aims to establish a coordinating center for the ReVAMPP Network.

RFA-AI-23-019, Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19, Clinical Trial Not Allowed)

This NOFO calls for Centers proposing research on virus families from Flaviviridae and Togaviridae to be part of the ReVAMPP Network.

The NOFO’s purpose is to establish comprehensive, cooperative basic and translational research Centers to carry out in-depth research on prototype members of select virus families that have the potential to emerge as pandemic pathogens. The goal of these Centers will be to develop vaccine and monoclonal antibody strategies for prototype pathogen(s) that can be applied to closely related family members based on shared functional and structural properties.

RFA-AI-23-020, Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae, and Picornaviridae (U19, Clinical Trial Not Allowed)

This NOFO solicits Centers proposing research on virus families from Bunyavirales, Paramyxoviridae, and Picornaviridae to be part of the ReVAMPP Network.

As with RFA-AI-23-019, this NOFO’s purpose is to establish comprehensive, cooperative basic and translational research Centers to carry out in-depth research on prototype members of select virus families that have the potential to emerge as pandemic pathogens. The goal of these Centers will likewise be to develop vaccine and monoclonal antibody strategies for prototype pathogen(s) that can be applied to closely related family members based on shared functional and structural properties.

Application Requirements for RFA-AI-23-019 and RFA-AI-23-020

ReVAMPP Centers must be structured to include an administrative core, a scientific advisory board, a data management core, up to three scientific cores, and at least two but no more than five interdependent research projects. These components are described with greater detail in the NOFOs.

Both of the NOFOs require that applicants propose research milestones. Near the end of Year 3, award recipients will submit a transition package which NIAID program staff will evaluate against each award’s stated milestones. Funding for Years 4 and 5 will be dependent on achievement of milestones, contribution to the ReVAMPP Network, programmatic priorities, and the availability of funding.

NIAID expects ReVAMPP Centers to have an established (or else plans to establish) collaboration with an industry partner that will provide access to vaccine expertise in manufacturing, clinical development, and regulatory pathways. Applications proposing investigational new drug-enabling translational research must include industry partnership.

The NOFOs also list several nonresponsive criteria, which your application must not include or else NIAID will not review it. For example, you cannot propose a clinical trial. Nor can you include toxicology studies or propose monoclonal antibody discovery and development in the absence of vaccine development. Find complete lists of excluded study types in the NOFOs themselves.

Your application budget should not exceed $10 million in annual direct costs and must reflect the actual needs of your proposed project. The scope of your proposed project should determine the project period, although you cannot exceed a maximum project period of 5 years.   

The application due date for both NOFOs is June 8, 2023, by 5 p.m. local time of the applicant organization.

Direct questions to NIAID’s scientific/research contact Dr. Kaitlyn Morabito at kaitlyn.dambach@nih.gov or 301-204-3248. For concerns about peer review specifically, contact Dr. Frank De Silva at fdesilva@niaid.nih.gov or 240-669-5023.

RFA-AI-23-021, Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network—Coordination and Data Sharing Center (CDSC) (UG3/UH3, Clinical Trial Not Allowed)

A third companion NOFO solicits applications to establish a Coordination and Data Sharing Center (CDSC) in support of the ReVAMPP Centers. The purpose of the CDSC is to support, coordinate, and manage ongoing and planned activities within the ReVAMPP Network.

The CDSC will establish and maintain a collaborative ReVAMPP Network platform for data sharing as needed to harmonize reagents, assays, and animal models and exchange knowledge on structure/function-based vaccine solutions and antigen/immunogen design as well as assess the utility of vaccine technology platforms for virus families studied under the ReVAMPP Centers. The CDSC will also facilitate effective communications across the ReVAMPP Centers by scheduling and managing all meetings, tracking overall network progress and outputs, developing opportunities for collaboration among the Centers such as establishing working groups, and collating information and facilitating exchange with other NIAID/NIH programs, U.S. government partners, and other key stakeholders.

NIAID intends to fund one award. Application budgets are not expected to exceed $1.5 million in direct costs per year and need to reflect the actual needs of the proposed project. The project period must be 5 years.

The due date for this NOFO is June 8, 2023, by 5 p.m. local time of the applicant organization.

Direct questions to NIAID’s scientific/research contact Dr. Kaitlyn Morabito at kaitlyn.dambach@nih.gov or 301-204-3248. For concerns about peer review, contact Dr. Frank De Silva at fdesilva@niaid.nih.gov or 240-669-5023.

Learn More

Find clarification to common applicant enquiries at Questions and Answers for ReVAMPP Funding Opportunities. NIAID will update the page as new questions arise. 

NIAID will host an informational webinar on April 14, 2023, at 1:00 pm Eastern Time. Register for the meeting at Informational Webinar for Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network Funding Opportunities.

Contact Us

Email us at deaweb@niaid.nih.gov for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on